Pregled bibliografske jedinice broj: 682513
Bortezomib in the treatment of concomitant multiple myeloma and secondary pulmonary amyloidosis
Bortezomib in the treatment of concomitant multiple myeloma and secondary pulmonary amyloidosis // Periodicum Biologorum / Vitale, Branko (ur.).
Zagreb: Hrvatsko prirodoslovno društvo, 2013. str. 57-57 (poster, domaća recenzija, sažetak, ostalo)
CROSBI ID: 682513 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Bortezomib in the treatment of concomitant multiple myeloma and secondary pulmonary amyloidosis
Autori
Radić Krišto, Delfa ; Mandac Rogulj, Inga ; Planinc-Peraica, Ana
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, ostalo
Izvornik
Periodicum Biologorum
/ Vitale, Branko - Zagreb : Hrvatsko prirodoslovno društvo, 2013, 57-57
Skup
7th Croatian Congress of Pharmacology with international participation
Mjesto i datum
Zagreb, Hrvatska, 18.09.2013. - 21.09.2013
Vrsta sudjelovanja
Poster
Vrsta recenzije
Domaća recenzija
Ključne riječi
bortezomib; multipli mijelom; amiloidoza
(bortezomib; multiple myeloma; amyloidosis)
Sažetak
Introduction: Bortezomib is the first U.S. Food and Drug Administration approved proteasome inhibitor used in the treatment of newly diagnosed multiple myeloma, relapsed/refractory multiple myeloma, and mantle cell lymphoma. Concomitant presentation of multiple myeloma and pulmonary amyloidosis is rare disorder with poor prognosis. We present a case of a 46-year old male with concomitant multiple myeloma and pulmonary amyloidosis who was successfully treated with bortezomib. Materials and methods: Clinical information was obtained from medical records, hematology and biochemical laboratory findings, cytopathology reports and radiologic imaging. Results: The patient was admitted to the hospital complaining to weakness, dyspnea and retrosternal pain. Computed tomography scan showed anterior mediastinal mass in the hypopharynx and larynx with the expansion back in prevertebral spaces. Multiple osteolytic lesions of the thoracic spine were detected. Tracheo- stomy was performed due to the extreme dyspnea caused by tumor compression of the trachea. Sternal mass biopsy verified 30% atypical plasma cells stage I and II with amyloid deposition. Bone marrow pathology was consistent with multiple myeloma while FISH analysis revealed heavy chain translocation t(11, 14). Other labo- ratory tests were normal, “M” component was not found. Induction chemotherapy consisted of 4 cycles of polychemotherapy VAD (vincristine, adriablastine, dexamethasone) followed by autologous stem cell trans- plantation. Reevaluation with PET-CT described residual mediastinal tumor. The treatment continued with 8 cycles of bortezomib and dexamethasone which resulted in complete remission. Conclusion: In these patients with concomitant multiple myeloma and secondary amyloidosis, who have residual disease following previous conventional therapies, bortezomib is effective treatment with excellent results.
Izvorni jezik
Engleski
Znanstvena područja
Biologija
POVEZANOST RADA
Projekti:
044-1081873-1281 - Hematološki poremećaji u bolesnika sa kardiomiopatijama (Planinc-Peraica, Ana, MZOS ) ( CroRIS)
Ustanove:
Klinička bolnica "Merkur"